Efungumab
Efungumab (trade name Mycograb) is a drug developed by NeuTec Pharma (a subsidiary of Novartis), intended to treat invasive Candida infection in combination with amphotericin B. The European Medicines Agency has twice refused to grant marketing authorization for Mycograb, citing product safety and quality issues. Chemically, efungumab is a single-chain variable fragment of a human monoclonal antibody.As such, it potentially act similarly to an IgA - inhibiting by binding and blocking.
Efungumab
Efungumab (trade name Mycograb) is a drug developed by NeuTec Pharma (a subsidiary of Novartis), intended to treat invasive Candida infection in combination with amphotericin B. The European Medicines Agency has twice refused to grant marketing authorization for Mycograb, citing product safety and quality issues. Chemically, efungumab is a single-chain variable fragment of a human monoclonal antibody.As such, it potentially act similarly to an IgA - inhibiting by binding and blocking.
has abstract
Efungumab (trade name Mycograb ...... ater found to be non-specific.
@en
L'efungumab nome commerciale M ...... A sull'antigene fungino Hsp90.
@it
إفونغوماب هو جسم مضاد وحيد الن ...... جاري كان مايكوغراب (Mycograb).
@ar
ATC prefix
FDA UNII code
BM86P708HW
Wikipage page ID
Wikipage revision ID
734,321,333
bioavailability
Not applicable
ChemSpiderID
elimination half-life
molecular weight
Approximately 27.2 kg/mol
protein bound
routes of administration
target
tradename
Verifiedfields
verifiedrevid
447,746,895
Watchedfields
subject
hypernym
comment
Efungumab (trade name Mycograb ...... iting by binding and blocking.
@en
L'efungumab nome commerciale M ...... A sull'antigene fungino Hsp90.
@it
إفونغوماب هو جسم مضاد وحيد الن ...... جاري كان مايكوغراب (Mycograb).
@ar
label
Efungumab
@en
Efungumab
@it
إفونغوماب
@ar